Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:24:18.765Z.
Calculation as of: 2026-10-06T22:24:18.765Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7
PE RATIO
N/A
Market Cap
$7.07M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.60M
PE Ratio
N/A
TTM Avg
4788.36
3Y Avg
147312.95
5Y Avg
148989.26
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.88M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A | 0.69 | 0.69 | 0.69 |
| Longeveron Inc. (LGVN)vs › | $7.15M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.61M | N/A | 278.25 | 163.06 | 336.05 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | N/A | 4788.36 | 147312.95 | 148989.26 |
| Aclarion, Inc. (ACON)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 47.75 | 83.50 | 106.23 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
